| 1.84 0 (0%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.59 |
1-year : | 2.9 |
| Resists | First : | 2.21 |
Second : | 2.49 |
| Pivot price | 2.1 |
|||
| Supports | First : | 1.77 |
Second : | 1.48 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 2.1 |
| MA(100) : | 1.89  |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 12.3 |
| RSI | RSI(14): 38.8 | |||
| 52-week | High : | 3.53 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CRBU ] has closed above bottom band by 14.5%. Bollinger Bands are 70.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.93 | 1.93 - 1.94 |
| Low: | 1.75 - 1.77 | 1.77 - 1.78 |
| Close: | 1.82 - 1.84 | 1.84 - 1.86 |
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Thu, 04 Jun 2026
CRBU: Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA - TradingView
Thu, 04 Jun 2026
CRBU: Pivotal-ready CAR T therapies advance in lymphoma and myeloma, with key data expected this year - TradingView
Sun, 31 May 2026
Caribou Biosciences (CRBU) Gets A Higher Target As Confidence In Its Pipeline Grows - Yahoo Finance
Thu, 28 May 2026
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Fri, 22 May 2026
CRBU SEC Filings - Caribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Wed, 13 May 2026
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 9.477e+007 (%) |
| Held by Institutions | 8.9 (%) |
| Shares Short | 6,770 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1416e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 96.3 % |
| Return on Equity (ttm) | -34.7 % |
| Qtrly Rev. Growth | 1.12e+007 % |
| Gross Profit (p.s.) | -0.98 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -101 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 16.26 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 7.14e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|